Literature DB >> 10386969

Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis.

N P Murphy1, N T Maidment.   

Abstract

Orphanin FQ has been reported to suppress extracellular dopamine levels in the nucleus accumbens after intracerebroventricular administration. This study sought to provide evidence for an intra-ventral tegmental site of action for this effect using a dual-probe microdialysis experimental design. Orphanin FQ was applied to the ventral tegmental area of anesthetized rats by reverse dialysis while extracellular dopamine was sampled with a second dialysis probe in the nucleus accumbens. Orphanin FQ at a probe concentration of 1 mM (but not at 0.1 mM) significantly reduced nucleus accumbens dialysate dopamine levels. The receptor-inactive analogue, des-Phe1-orphanin FQ (1 mM), produced a small but significant increase in nucleus accumbens dialysate dopamine levels. Simultaneous measurement of ventral tegmental area dialysate amino acid content revealed significant increases in both GABA and glutamate during infusion of orphanin FQ (1 mM). To determine if increased GABA overflow mediates the action of orphanin FQ on mesolimbic neurons, orphanin FQ (10 nmol) was microinjected directly into the ventral tegmental area in the presence or absence of the GABA(A) receptor antagonist, bicuculline (1 nmol). Bicuculline transiently blocked the suppressive action of orphanin FQ on accumbens dialysate dopamine levels. These data indicate that orphanin FQ decreases dopamine transmission in the nucleus accumbens by inhibiting dopamine neuronal activity in the ventral tegmental area through a mechanism that may involve an increased overflow of GABA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10386969     DOI: 10.1046/j.1471-4159.1999.0730179.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  55 in total

1.  Inhibition of striatal and retinal dopamine release via nociceptin/orphanin FQ receptors.

Authors:  K Flau; A Redmer; S Liedtke; M Kathmann; E Schlicker
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 2.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

3.  Orphanin FQ/nociceptin not only blocks but also reverses behavioral adaptive changes induced by repeated cocaine in mice.

Authors:  David Bebawy; Paul Marquez; Seroje Samboul; Drupad Parikh; Abdul Hamid; Kabirullah Lutfy
Journal:  Biol Psychiatry       Date:  2010-03-31       Impact factor: 13.382

4.  A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.

Authors:  Nurulain T Zaveri; Paul V Marquez; Michael E Meyer; Willma E Polgar; Abdul Hamid; Kabirullah Lutfy
Journal:  Alcohol Clin Exp Res       Date:  2018-01-19       Impact factor: 3.455

Review 5.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

6.  Chronic cocaine produces decreases in N/OFQ peptide levels in select rat brain regions.

Authors:  Patrizia Romualdi; Manuela Di Benedetto; Claudio D'Addario; Stephanie L Collins; Dean Wade; Sanzio Candeletti; Sari Izenwasser
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

Review 7.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

8.  Involvement of NMDAR2A tyrosine phosphorylation in depression-related behaviour.

Authors:  Sachiko Taniguchi; Takanobu Nakazawa; Asami Tanimura; Yuji Kiyama; Tohru Tezuka; Ayako M Watabe; Norikazu Katayama; Kazumasa Yokoyama; Takeshi Inoue; Hiroko Izumi-Nakaseko; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura; Hisashi Umemori; Takafumi Inoue; Niall P Murphy; Kouichi Hashimoto; Masanobu Kano; Toshiya Manabe; Tadashi Yamamoto
Journal:  EMBO J       Date:  2009-10-15       Impact factor: 11.598

9.  The role of NOP receptors in psychomotor stimulation and locomotor sensitization induced by cocaine and amphetamine in mice.

Authors:  Paul Marquez; Abdul Hamid; Kabirullah Lutfy
Journal:  Eur J Pharmacol       Date:  2013-03-21       Impact factor: 4.432

10.  Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors.

Authors:  Alexander Kuzmin; Johan Sandin; Lars Terenius; Sven Ove Ogren
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.